FEATURED ARTICLES

• Early-Stage Biotech's AI Advantage Is A Window That Closes

  FDA AI guidance won’t build your strategy for you. Learn how biotech teams can avoid retrofits and design smarter clinical AI from day one.

• Meeting The FDA's New Real-World Evidence Standards

  FDA guidance is reshaping RWE strategy. Sponsors that build interoperable, audit-ready RWD infrastructure now will be best positioned for faster, defensible submissions.

• Where PRO Strategy Goes Wrong

  PRO and COA strategy is now central to trial success. Organizations that capture meaningful patient experience data will gain stronger evidence and a regulatory advantage.

• Is The Industry Ready To Trust LLMs With Chart Review?

  See how LLM-powered extraction transforms unstructured medical records into compliant, audit-ready clinical data with machine-scale speed, human oversight, and regulatory-grade accuracy.

• The eCOA Iceberg

  Understand the true cost of eCOA deployment, beyond software licenses, to reduce protocol risk, avoid operational bottlenecks, and protect study timelines and data quality.

• Optimizing Data Capture From Protocol Design To Efficacy Endpoints

  The shift to digital trials favors the 11-point NRS over the traditional VAS to reduce data noise, improve elderly patient compliance, and ensure statistical power across mobile devices.

• Own Your Data, Accelerate Your Cure

  Move from passive donor to active innovator. Explore how patient communities are building their own research infrastructure and using AI to bypass traditional barriers to drug development.

• A Blueprint For Modern Obesity Research

  The landscape of obesity and GLP-1 research has reached a saturation point. To successfully scale to the 5,000-patient registries now required for long-term evidence, a shift in operational architecture is essential.

• Strong Bookings And The Disruption Gap Nobody Is Talking About

  Understand the real impact of AI on CRO valuations and clinical trial stability. Explore why market data contradicts the "disruption" narrative and what it means for the future of the industry.

• Early-Stage Biotech's AI Advantage Is A Window That Closes

  The "greenfield" advantage allows biotechs to build AI-native trials from the start, replacing manual data entry with automated workflows and structured human oversight for better data integrity.

• What AI Replaces In Phase 2/3 Data Management

  Explore how clinical teams are moving beyond AI hype to implement grounded strategies for automated edit checks, risk-based query management, and the regulatory frameworks needed for oversight.

• Real-Time Data... Are We Fixing The Right Bottleneck (Or Any For That Matter)?

  Real-time data streaming to regulators is a bold step, but true clinical acceleration requires solving site-level bottlenecks and data silos to reduce the administrative burden on research.

• Reinventing Prostate Cancer Diagnostics With An All-In-One Platform

  Discover how a lean research team saved an estimated $100k and reached 95% data compliance by unifying their clinical workflow.

• From Months To Hours: MMC Medical's EDC Revolution

  Learn how a specialized CRO reduced study build times by 95%. Discover strategies for template reusability and flexible resource scaling to accelerate early-stage medical device validation.

• Executing Concurrent Decentralized RCTs And RWE At Scale

  See how a team of four managed data for 40 peer-reviewed studies and 200,000 participants.

• 3-Week Database Builds That Withstood FDA Review

  Learn how a lean clinical team deployed global, regulator-ready databases in just three weeks to secure immediate Phase 3 entry and transform reproductive health research.

• The Patient Experience Paradox: eCOA Strategy Overhaul

  European regulatory shifts now require the systematic integration of patient data. Success depends on aligning clinical and market access strategies through rigorous evidence generation.

• Implications Of Assessing Overall Survival In Oncology Studies

  New oncology standards mandate pre-specified survival analysis to catch long-term harm. Learn how to implement hazard ratio thresholds and the ICH E9(R1) framework for global compliance.

• The Silent Saboteurs: Why Rater Drift And Site Unpreparedness Cost CNS Trials More

  High-end technology cannot fix poor rater preparation or complex patient needs. True data integrity requires bridging the gap between digital platforms and the reality of clinical implementation.

• The End Of The "PRO Tax": Top 10 Commercial PROs & Their Cost-Effective Alternatives

  Regulators now prioritize fit-for-purpose data over legacy instrument brand names. Modernizing your assessment strategy reduces licensing delays and improves trial startup speed and efficiency.